Rapid determination of gemifloxacin in human plasma by high-performance liquid chromatography-tandem mass spectrometry

被引:60
作者
Doyle, E [1 ]
Fowles, SE [1 ]
McDonnell, DF [1 ]
McCarthy, R [1 ]
White, SA [1 ]
机构
[1] SmithKline Beecham Pharmaceut, Dept Drug Anal, Welwyn Garden City AL6 9AR, Herts, England
来源
JOURNAL OF CHROMATOGRAPHY B | 2000年 / 746卷 / 02期
关键词
gemifloxacin;
D O I
10.1016/S0378-4347(00)00333-9
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A method was developed for the determination of gemifloxacin (I) in human plasma using high-performance liquid chromatography-tandem mass spectrometry. Prior to analysis, the protein in plasma samples was precipitated with acetonitrile containing [(CH3)-C-13-H-2] gemifloxacin (II) to act as an internal standard. The supernatant was injected onto a PLRP-S column without any further clean-up. The mass spectrometer was operated in positive ion mode, employing a heat assisted nebulisation, electrospray interface. Ions were detected in multiple reaction monitoring (MRM) mode. The assay requires 50 mu l of plasma and is precise and accurate within the range 10-5000 ng/ml. The average within-run and between-run coefficients of variation were <11% at 10 ng/ml and greater concentrations. The average accuracy of validation standards was generally within +/-7% of the nominal concentration. There was no evidence of instability of I in human plasma following three complete freeze-thaw cycles and samples can safely be stored for at least 6 months at -20 degrees C. The method proved very robust and was successfully applied to the analysis of clinical samples from patients dosed with gemifloxacin. (C) 2000 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:191 / 198
页数:8
相关论文
共 5 条
[1]   Effect of Maalox® on the bioavailability of oral gemifloxacin in healthy volunteers [J].
Allen, A ;
Vousden, M ;
Porter, A ;
Lewis, A .
CHEMOTHERAPY, 1999, 45 (06) :504-511
[2]   Effect of omeprazole on the pharmacokinetics of oral gemifloxacin in healthy volunteers [J].
Allen, A ;
Vousden, M ;
Lewis, A .
CHEMOTHERAPY, 1999, 45 (06) :496-503
[3]   Antimicrobial activity and spectrum of LB20304, a novel fluoronaphthyridone [J].
Cormican, MG ;
Jones, RN .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (01) :204-211
[4]  
Hohl Annik F., 1998, Clin Microbiol Infect, V4, P280
[5]   In vitro and in vivo evaluations of LB20304, a new fluoronaphthyridone [J].
Oh, JI ;
Paek, KS ;
Ahn, MJ ;
Kim, MY ;
Hong, CY ;
Kim, IC ;
Kwak, JH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (06) :1564-1568